Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zanamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 7/20 | 0.72 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.70 |
| ▸ | NEU4 | Q8WWR8 | 5/20 | 0.70 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zanamivir SCHEMBL13169991 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL3497032 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL14080017 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL11946705 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL12367840 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL496815 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL15448958 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13459831 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13693731 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA | |
| Zanamivir SCHEMBL13980833 | 1.00 | NEU2 (0.72) | NEU2NEU3NEU4NEU1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222318-B1 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO LTD (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-8470378-B2 | Anti-influenza viral composition containing bark or stem extract of Alnus japonica | RNL BIO CO., LTD (KR) | 2013-06-25 | — | — | US | disclosed |
| US-8426370-B2 | Diaryl hepatonoid-based compounds and use thereof | RNL BIO CO., LTD. (KR) | 2013-04-23 | — | — | US | disclosed |
| CN-102215851-B | Anti-influenza virus composition containing extract of bark or stem of alnus japonica | RNL BIO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| EP-2561365-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120173285-A1 | Proactive Clinical Evidence at Point of Care and Genomic Data Integration through Cloud EMR Media | MUTHUKRISHNAN SURESH (QA) | 2012-07-05 | — | — | US | disclosed |
| US-20120164253-A1 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD. (KR) | 2012-06-28 | — | — | US | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011133719-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110098239-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | RNL BIO CO., LTD. (KR) | 2011-04-28 | — | — | US | disclosed |
| US-20100285160-A1 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD. (KR) | 2010-11-11 | — | — | US | disclosed |
| EP-2222318-A2 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL Bio Co., Ltd. (KR) | 2010-09-01 | — | — | EP | disclosed |
| US-20100189827-A1 | ANTIVIRAL COMPOSITION COMPRISING ALNUS JAPONICA EXTRACTS | RNL BIO CO., LTD. (KR) | 2010-07-29 | — | — | US | disclosed |
| US-20090175963-A1 | ANTIVIRAL COMPOSITION COMPRISING LYCORIS SQUAMIGERA EXTRACTS | RNL BIO CO., LTD (KR) | 2009-07-09 | — | — | US | disclosed |
| WO-2009075488-A2 | ANTI-INFLUENZA VIRAL COMPOSITION CONTAINING BARK OR STEM EXTRACT OF ALNUS JAPONICA | RNL BIO CO., LTD (KR) | 2009-06-18 | — | — | WO | disclosed |
| US-20090142418-A1 | ANTIVIRAL COMPOSITION COMPRISING ALNUS JAPONICA EXTRACTS | RNL BIO CO., LTD. (KR) | 2009-06-04 | — | — | US | disclosed |
| WO-2008001976-A1 | ANTIVIRAL COMPOSITION COMPRISING ALNUS JAPONIC EXTRACTS | RNL BIO CO., LTD. (KR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001974-A1 | ANTIVIRAL COMPOSITION COMPRISING LYCORIS SQUAMIGERA EXTRACTS | RNL BIO CO., LTD (KR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001968-A1 | ANTIVIRAL COMPOSITION COMPRISING ALNUS PENDULA EXTRACTS | RNL BIO CO., LTD (KR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098239-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | HAVCR2, SLC10A1, CYP7A1 | NEU2 1262/4885NEU3 1020/4885NEU4 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.